REG-STRATEGY CONSULTING

(8) Pan, G., Shawer, M., Øie, S. and Lu, D. R.: In vitro gene transfection to glioma cells using a novel and less cytotoxic artificial lipoprotein delivery system. Pharmaceutical Research, 20, 738-745 (2003)... (9) Shawer, M., Greenspan, P., Øie, S. and Lu, D. R.: VLDL-resembling phospholipid-submicron emulsion for cholesterol-based drug targeting. Journal of Pharmaceutical Sciences, 91, 1405-1413 (2002)... Dr. Donghao (Robert) Lu is a drug development expert and a Regulatory and CMC consultant (President and Chief Consultant, Reg-Strategy Consulting, LLC, USA). Currently Dr. Lu carries out his consulting work (%FTE freelance, i.e. part-time employee) with China and US pharmaceutical companies, for their regulatory and CMC development and submissions (Phase 1-2-3, NDA) on small molecules. In addition, since left FDA, he provided regulatory consulting at Parexel International Corp. (USA) and for several famous Chinese pharmaceutical companies (including Chinese medicine); and..

Also known as: Reg-Strategy Consulting, LLC